Three biotechnology companies went public in a single night on 30 January when Ultragenyx, Trevena and Cara Therapeutics launched initial public offerings and Intra-Cellular Therapies priced an additional IPO to move its stock to the Nasdaq index.
Three biotechnology companies went public in a single night on 30 January when Ultragenyx, Trevena and Cara Therapeutics launched initial public offerings and Intra-Cellular Therapies priced an additional IPO to move its stock to the Nasdaq index.
The barrage of newly public therapeutics companies followed a tripling of the Dicerna Pharmaceuticals stock price versus its IPO value...
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
